Zobrazeno 1 - 8
of 8
pro vyhledávání: '"John M, Fastenau"'
Autor:
Thomas, Martin, Yi, Lin, Mounzer, Agha, Adam D, Cohen, Myo, Htut, A Keith, Stewart, Parameswaran, Hari, Jesus G, Berdeja, Saad Z, Usmani, Tzu-Min, Yeh, Yunsi, Olyslager, Jenna D, Goldberg, Jordan M, Schecter, Deepu, Madduri, Carolyn C, Jackson, William, Deraedt, Katharine S, Gries, John M, Fastenau, Jeremiah J, Trudeau, Muhammad, Akram, Lida, Pacaud, Andrzej, Jakubowiak, Sundar, Jagannath
Publikováno v:
The Lancet Haematology. 9:e897-e905
CARTITUDE-1 is a phase 1b-2 study evaluating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple mye
Autor:
Katie Baca-Motes, Alison M. Edwards, Jill Waalen, Shawn Edmonds, Rajesh R. Mehta, Lauren Ariniello, Gail S. Ebner, Dimitri Talantov, John M. Fastenau, Chureen T. Carter, Troy C. Sarich, Elise Felicione, Eric J. Topol, Steven R. Steinhubl
Publikováno v:
Contemporary Clinical Trials Communications, Vol 14, Iss , Pp - (2019)
Objectives: The advent of large databases, wearable technology, and novel communications methods has the potential to expand the pool of candidate research participants and offer them the flexibility and convenience of participating in remote researc
Externí odkaz:
https://doaj.org/article/88e2d93e61aa4cadbc2595f6095fba55
Autor:
Adam D. Cohen, Parameswaran Hari, Myo Htut, Jesus G. Berdeja, Saad Z. Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Carolyn C. Jackson, Katharine S. Gries, John M. Fastenau, Satish Valluri, William Deraedt, Muhammad Akram, Rebecca Crawford, Ross Morrison, Lynda Doward, Kate Morgan, Silene ten Seldam, Andrzej Jakubowiak, Sundar Jagannath
Publikováno v:
Clinical lymphoma, myelomaleukemia. 23(1)
Ciltacabtagene autoleucel (cilta-cel), a novel chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated early, deep, and durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), and improve
Publikováno v:
Wound Repair and Regeneration. 8:251-257
Several recent advances in wound care may offer promise for the treatment of hard-to-heal venous leg ulcers. One such treatment is Apligraf (Graftskin), a bilayered, living human skin construct. To assess the economic impact of Graftskin, a model was
Publikováno v:
Journal of managed care pharmacy : JMCP. 10(6)
For individuals with chemotherapy-related anemia, the clinical effectiveness of epoetin alfa (EPO) dosed once weekly ([QW], 40,000 units per dose) has been demonstrated to be indistinguishable from that observed with thrice-weekly dosing ([TIW], 10,0
Publikováno v:
Blood. 104:3154-3154
Background: Patients with acute myeloid leukemia (AML) have an estimated median age of 65 to 70 years (J Clin Oncol1999;17:3569–76). The overall incidence of the disease increases with increasing age. The five-year survival rate for AML is 2% among
Publikováno v:
Blood. 104:5307-5307
Background: Understanding patients’ preferences regarding treatment features is important, as they may not be aligned with those of providers. Epoetin alfa (EPO) and darbepoetin alfa (DARB) are two erythropoietic agents indicated for the treatment
Autor:
Corey J. Langer, John M. Fastenau, Jamie B. Forlenza, Catherine Tak Piech, Susan C. Bolge, Jennifer Gano Allen, Marya D. Zilberberg
Publikováno v:
Current Medical Research & Opinion; Jan2007, Vol. 23 Issue 1, p85-92, 8p